沙库巴曲缬沙坦在心力衰竭治疗中的研究进展  

Sacubitril/valsartan in Treatment of Heart Failure

作　　者：潘东 罗勇[1] PAN Dong;LUO Yong(Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)

机构地区：[1]川北医学院附属医院,四川南充637000

出　　处：《心血管病学进展》2020年第2期114-117,共4页Advances in Cardiovascular Diseases

摘　　要：心力衰竭是各类心脏疾病的终末阶段,既往尽管使用了临床指南推荐的治疗,心力衰竭患者的愈后仍欠佳。血管紧张素受体-脑啡肽酶抑制剂沙库巴曲缬沙坦是一种新型的治疗心力衰竭药物,因其卓越的疗效,越来越受到人们关注,现就沙库巴曲缬沙坦作用机制、临床研究结果、临床指南推荐及使用方案等方面做一阐述。Heart failure is the end stage of various kinds of heart diseases.Although the treatment recommended by the clinical guidelines has been used,the treatment effect of heart failure is still unsatisfactory.Angiotensin receptor neprilysin inhibitor sacubitril/valsartan is a new type of heart failure treatment drug.Due to its excellent curative effect,it has attracted more and more attention.In this article,the mechanism,clinical research results,clinical guidelines recommendation and adminstration plan were discussed.

关 键 词：沙库巴曲缬沙坦 血管紧张素受体-脑啡肽酶抑制剂 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]